Novanta to Report Third-Quarter Results After Close, Set Conference for November 10
Key Facts
Novanta said it will release its third-quarter 2026 results after the close of U.S. financial markets on Monday, November 9, according to a schedule published by the company’s investor relations team. The schedule sets the announcement date but does not include the results themselves. The company is scheduled to hold a conference to discuss the results on Tuesday, November 10, at 8:00 a.m. Eastern Time. The timing will allow investors to review the results and discuss them with the company after their release. The announcement follows quarterly and annual forecasts Novanta previously issued after its second-quarter results.
Novanta’s third-quarter guidance called for generally accepted accounting principles revenue of $300 million to $304 million, with growth exceeding 21%. The company also forecast adjusted diluted earnings per share of $0.95 to $1.00 for the period. These figures represent the company’s prior expectations for the quarter, not results announced on November 9. The guidance alone therefore cannot establish whether actual revenue or earnings per share exceeded those ranges. The key comparison when the results are released will be actual revenue and earnings per share against those thresholds.
The company raised its fiscal 2026 forecast after reporting second-quarter results, setting generally accepted accounting principles revenue at $1.130 billion to $1.140 billion. The annual guidance also included adjusted diluted earnings per share of $3.68 to $3.74. This annual range places third-quarter results in the context of the company’s expectations for the rest of the year, but does not by itself establish that guidance changed or that those levels were achieved. Assessing the annual trajectory depends on the quarter’s actual figures and any update the company issues to its forecasts. Novanta scheduled its November 10 conference to discuss the results with investors.
The company said its third-quarter and full-year guidance incorporates the expected contribution from the Riverpoint Medical acquisition. The guidance also assumes no significant changes in exchange rates. That means the published revenue and earnings-per-share estimates were tied to the company’s expectations for the acquisition’s impact and relative stability in foreign currencies. The available information does not specify the amount Riverpoint Medical was expected to contribute to the forecasts. It also does not detail the actual impact of exchange rates during the quarter or whether the company adjusted these assumptions when it announced the results.
As a reference for the quarterly comparison, Novanta’s second-quarter 2026 net income under generally accepted accounting principles was $12.5 million, compared with $4.5 million in the same period of 2025. Diluted earnings per share in the second quarter was $0.30, compared with $0.12 a year earlier. These prior results provide a benchmark for the period before the third quarter, but do not reveal net income or earnings per share for the quarter whose results the company scheduled for November 9. Nor does this comparison establish the direction of third-quarter earnings without the new quarterly figures.
Ahead of the results, Novanta shares closed at $146.24 on November 2, then at $147.49 on November 3 and $145.23 on November 4, according to EL7 data. The closing price fell to $131.82 on November 5 before rising to $135.15 on November 6. These prices precede the results announcement after the market close on November 9, so they record the stock’s performance in prior sessions and do not represent a market reaction to the announcement. The conference is scheduled for the morning of November 10 Eastern Time, after the results are released, to discuss them with the company.